CERS
Cerus Corporation NASDAQ Listed Jan 31, 1997$2.62
Mkt Cap $524.0M
52w Low $1.15
73.3% of range
52w High $3.15
50d MA $2.01
200d MA $1.81
P/E (TTM)
-33.2x
EV/EBITDA
-35.0x
P/B
8.0x
Debt/Equity
1.5x
ROE
-24.3%
P/FCF
46.1x
RSI (14)
—
ATR (14)
—
Beta
1.63
50d MA
$2.01
200d MA
$1.81
Avg Volume
1.5M
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
1220 Concord Avenue · Concord, CA 94520 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -0.03 | -0.01 | +66.7% | 2.03 | +32.5% | +34.0% | +34.0% | +27.6% | +27.6% | +28.6% | — |
| Mar 2, 2026 | AMC | -0.01 | -0.01 | +0.0% | 2.53 | -15.4% | -15.8% | -11.5% | -19.4% | -23.7% | -23.7% | — |
| Nov 6, 2025 | AMC | -0.02 | -0.00 | +99.5% | 1.41 | +1.4% | +21.3% | +13.5% | +17.0% | +17.0% | +13.5% | — |
| Aug 5, 2025 | AMC | -0.02 | -0.03 | -50.0% | 1.28 | +0.0% | +0.8% | -3.1% | -5.5% | -2.3% | +0.8% | — |
| May 1, 2025 | AMC | -0.05 | -0.04 | +20.0% | 1.30 | -1.5% | +3.8% | +0.0% | -3.8% | +0.0% | +4.6% | — |
| Feb 20, 2025 | AMC | -0.01 | -0.01 | +0.0% | 1.74 | +1.7% | -5.2% | -5.7% | -6.3% | -5.7% | -8.6% | — |
| Oct 30, 2024 | AMC | -0.01 | -0.02 | -33.3% | 1.72 | +4.7% | -8.7% | -11.6% | -9.3% | -3.5% | +5.2% | — |
| Aug 1, 2024 | AMC | -0.02 | -0.03 | -25.0% | 2.04 | +5.4% | +15.2% | +8.8% | +7.4% | +2.5% | +6.9% | — |
| May 2, 2024 | AMC | -0.05 | -0.05 | -7.1% | 1.76 | +3.4% | -8.0% | +1.7% | +5.1% | +6.8% | +8.5% | — |
| Mar 5, 2024 | AMC | -0.01 | -0.01 | -58.5% | 1.99 | +7.5% | +21.6% | +19.6% | +13.6% | +10.1% | +7.5% | — |
| Nov 2, 2023 | AMC | -0.05 | -0.03 | +40.0% | 1.59 | +2.5% | +8.8% | +6.9% | +8.8% | +5.0% | -3.1% | — |
| Aug 2, 2023 | AMC | -0.05 | -0.07 | -40.0% | 2.98 | -8.2% | -18.0% | -18.3% | -26.2% | -31.3% | -34.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | BTIG | Upgrade | Neutral → Buy | — | $2.03 | $2.69 | +32.5% | +34.0% | +34.0% | +27.6% | +27.6% | +28.6% |
| May 1 | BTIG Research | Upgrade | Neutral → Buy | $4 | $2.03 | $2.69 | +32.5% | +34.0% | +34.0% | +27.6% | +27.6% | +28.6% |
| Feb 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.74 | $1.77 | +1.7% | -5.2% | -5.7% | -6.3% | -5.7% | -8.6% |
| Oct 17 | Stifel | Maintains | Buy → Buy | — | $1.80 | $1.63 | -9.4% | -9.4% | -5.6% | -6.7% | -9.4% | -10.6% |
| May 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.76 | $1.82 | +3.4% | -8.0% | +1.7% | +5.1% | +6.8% | +8.5% |
| Mar 7 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $2.42 | $2.50 | +3.3% | -1.7% | -6.6% | -9.5% | -11.6% | -16.1% |
| Mar 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.99 | $2.14 | +7.5% | +21.6% | +19.6% | +13.6% | +10.1% | +7.5% |
| Jan 20 | BTIG | Downgrade | Buy → Neutral | — | $3.10 | $3.14 | +1.3% | +0.6% | +0.6% | +0.6% | +0.0% | +0.0% |
| May 27 | Stifel | Maintains | Buy → Buy | — | $5.96 | $6.07 | +1.8% | -0.2% | +2.0% | +4.4% | +8.9% | +7.6% |
| Apr 16 | Stephens & Co. | Maintains | Overweight → Overweight | — | $5.03 | $5.08 | +1.0% | +2.2% | +4.8% | +8.2% | +2.4% | +5.8% |
| Feb 26 | BTIG Research | Maintains | Buy → Buy | — | $4.90 | $5.07 | +3.5% | +7.1% | +5.7% | +4.9% | +4.2% | +2.7% |
| Feb 26 | BTIG | Maintains | Buy → Buy | — | $4.90 | $5.07 | +3.5% | +7.1% | +5.7% | +4.9% | +4.2% | +2.7% |
| Nov 13 | BTIG Research | Upgrade | Neutral → Buy | — | $4.28 | $4.51 | +5.4% | +0.7% | +1.4% | +4.4% | +2.1% | +0.9% |
| Nov 13 | BTIG | Upgrade | Neutral → Buy | — | $4.28 | $4.51 | +5.4% | +0.7% | +1.4% | +4.4% | +2.1% | +0.9% |
| Aug 28 | Stifel | Maintains | Buy → Buy | — | $5.21 | $5.35 | +2.7% | +2.3% | +2.3% | +3.1% | +1.3% | -3.5% |
| Apr 22 | BTIG Research | Maintains | Buy → Buy | — | $6.65 | $6.75 | +1.5% | +0.0% | -2.6% | -3.0% | -2.7% | -3.5% |
| Apr 22 | BTIG | Maintains | Buy → Buy | — | $6.65 | $6.75 | +1.5% | +0.0% | -2.6% | -3.0% | -2.7% | -3.5% |
| Dec 17 | Wedbush | Downgrade | Outperform → Neutral | — | $6.59 | $6.34 | -3.8% | -10.0% | -10.5% | -11.1% | -12.4% | -9.1% |
| Apr 24 | BTIG Research | Maintains | Buy → Buy | — | $4.58 | $4.65 | +1.4% | +4.5% | +2.5% | -1.4% | -2.7% | -3.2% |
| Feb 27 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $5.35 | $5.16 | -3.6% | -10.7% | -16.6% | -17.0% | -16.6% | -16.8% |
| Dec 2 | MLV & Co. | Maintains | Buy → Buy | — | $4.29 | $4.31 | +0.5% | -0.7% | -1.4% | -1.2% | +0.5% | +0.5% |
| May 5 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $3.84 | $3.88 | +1.0% | +7.6% | +2.6% | +0.5% | -1.0% | +1.3% |
| Sep 30 | Wedbush | Maintains | Outperform → Outperform | — | $6.34 | $6.28 | -0.9% | +6.0% | +7.1% | +9.0% | +7.9% | +8.0% |
| Mar 1 | McNicoll Lewis Vlak | Maintains | Buy → Buy | — | $3.29 | $3.49 | +6.1% | +11.2% | +20.1% | +21.6% | +23.7% | +27.7% |
| Feb 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.18 | $3.17 | -0.3% | -0.6% | -1.9% | -2.5% | -4.4% | -5.3% |
| Oct 8 | Cowen & Co. | Maintains | Outperform → Outperform | — | $3.36 | $3.47 | +3.3% | +2.4% | +1.2% | +2.1% | +1.8% | +1.2% |
| Apr 17 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $3.65 | $3.73 | +2.2% | +5.8% | +3.3% | +5.5% | +6.6% | +3.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Jayaraman Vivek K | Chief Operating Officer | Sell | 16,667 | $3.00 | $50K | 1,673,374 | +0.00% | — |
8-K
Cerus Corporation -- 8-K Filing
Cerus Corporation raised 2025 product revenue guidance and outlined multiple 2026 catalysts including European INTERCEPT RBC regulatory decision and U.S. Phase 3 RedeS trial results, positioning for potential significant commercial expansion.
Apr 30
8-K · 5.02
!!! Very High
Cerus Corp -- 8-K 5.02: Executive Change
Cerus Corp lost two board members with the resignations of Kevin D. Green and Chrystal N. Jensen as directors.
Apr 21
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
CERS's change in executive leadership could signal strategic shifts in operations or performance concerns, making it crucial for investors to assess whether the new direction strengthens competitive positioning.
Mar 16
8-K
Cerus Corp -- 8-K Filing
Cerus Corp achieved record 2025 kit shipments for its INTERCEPT blood safety system, treating an estimated 600,000 patients globally and demonstrating strong commercial execution.
Mar 2
Data updated apr 25, 2026 12:47am
· Source: massive.com